ReviewMolecules (Basel, Switzerland)2020
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
200 citing papers in PubMed, 6 syntheses or guidelines pooled it, 468 citations in OpenAlex.
- Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.Journal of diabetes investigation · 2026 · on this mapPooled it
- Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis.Diabetologia · 2026Pooled it
- Common miRNAs, Genes, and Regulatory Pathways in Alzheimer's Disease and Type 2 Diabetes Mellitus: An Integrative Analysis of Systematic Reviews, Bioinformatics and Data Mining.Journal of neurochemistry · 2025Pooled it
- Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.Scientific reports · 2023Pooled it
- A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?Frontiers in endocrinology · 2023 · on this mapPooled it
- The Effects of Curcumin on Diabetes Mellitus: A Systematic Review.Frontiers in endocrinology · 2021Pooled it
- GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.Cell reports. Medicine · 2026Trial
- Pharmacokinetics, Pharmacodynamics, and Safety of Olorigliflozin in Individuals with Type 2 Diabetes Mellitus with or without Renal Impairment: A Single-Center, Single-Dose, Open-Label Trial.Clinical pharmacokinetics · 2025Trial
- The Impact of Low-Volume High-Intensity Interval Training (LV-HIIT) on Fatty Liver Index (FLI) and Estimated Glomerular Filtration Rate (eGFR) in Patients with Type 2 Diabetes Mellitus (T2DM).Current diabetes reviews · 2025Trial
- Empagliflozin's role in early tubular protection for type 2 diabetes patients.Molecular medicine (Cambridge, Mass.) · 2024Trial
- Assessing pyridoxine adjuvant therapy effects on blood glucose levels in type 2 diabetes: A randomized clinical trial.Journal of medicine and life · 2023 · on this mapTrial
- Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.Endocrinology, diabetes & metabolism · 2022Trial
- The Effect of Health Education Combined with Personalized Psychological Nursing Intervention on Pregnancy Outcome of Pregnant Women with Gestational Diabetes Mellitus.BioMed research international · 2022Trial
- Peptidomics-guided 3D structural-mechanistic investigation of bovine colostrum peptides reveals multi-targetedFood chemistry: X · 2026Article
- Design, Synthesis, Molecular Dynamics, and In Vitro Evaluation of Isatin-Based Quinazoline Derivatives as Potential Antidiabetic Agents.Chemistry & biodiversity · 2026Article
- Mining of Novel Human DPP-IV-Targeting Tripeptides through Multicomputational Screening and In Vitro Validation for Diabetes Therapy.ACS omega · 2026Article
- Antidiabetic Properties ofLife (Basel, Switzerland) · 2026Review
- A novel score to evaluate nonlinear association between insulin resistance and new-onset diabetes mellitus: A cohort analysis.Medicine · 2026Article
- Computational discovery of fenugreek-paitan-turmeric (FPT) bioactive compounds targeting SGLT2 and DPP-4 for glucose homeostasis regulation.Journal of Taibah University Medical Sciences · 2026Article
- Potential of Triazines as Antidiabetic Agents-A Review of Structures and Pharmacological Activity.Pharmaceuticals (Basel, Switzerland) · 2026Review
140 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90-95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes. In particular, the review considers the main systems directly involved in T2DM or involved in diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as on peroxisome proliferation activated receptors are considered. Inhibitors which target either aldose reductase and tyrosine phosphatase 1B or sodium glucose transporters 1 and 2 are taken into account. Moreover, with a view at the multi-target approaches for T2DM some phytocomplexes are also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.